{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:56:24Z","timestamp":1794020184644,"version":"4.8.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104741","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:11:49Z","timestamp":1772093509000},"page":"104741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody\u2013drug conjugates in breast cancer"],"prefix":"10.1016","volume":"86","author":[{"given":"Xiaoyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saige","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104741_bib1","first-page":"453","article-title":"Economic evaluation of trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer in the United States","volume":"14","author":"Lang","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104741_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.breast.2023.01.005","article-title":"How I treat HER2-low advanced breast cancer","volume":"67","author":"Schlam","year":"2023","journal-title":"Breast"},{"issue":"19","key":"10.1016\/j.breast.2026.104741_bib3","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2026.104741_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104741_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104090","article-title":"Next-generation antibody-drug conjugates for breast cancer: moving beyond HER2 and TROP2","volume":"190","author":"Schlam","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.breast.2026.104741_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104189","article-title":"The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: a systematic review","volume":"192","author":"Filis","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2746","key":"10.1016\/j.breast.2026.104741_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/bmj.2.2746.353","article-title":"Address in pathology, ON CHEMIOTHERAPY: delivered before the seventeenth international congress of medicine","volume":"2","author":"Ehrlich","year":"1913","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.breast.2026.104741_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00262-012-1369-3","article-title":"Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake","volume":"62","author":"Gorovits","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.breast.2026.104741_bib9","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci Rep"},{"key":"10.1016\/j.breast.2026.104741_bib10","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"10.1016\/j.breast.2026.104741_bib11","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.breast.2026.104741_bib12","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-025-02149-3","article-title":"ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"10","author":"Hu","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"issue":"32","key":"10.1016\/j.breast.2026.104741_bib14","article-title":"A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41523-023-00522-5","article-title":"Phase I study of A166, an antibody\u2012drug conjugate in advanced HER2-expressing solid tumours","volume":"9","author":"Zhang","year":"2023","journal-title":"npj Breast Cancer"},{"issue":"10","key":"10.1016\/j.breast.2026.104741_bib16","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1535-7163.MCT-20-0237","article-title":"PF-06804103, A site-specific Anti-HER2 antibody-drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers","volume":"19","author":"Graziani","year":"2020","journal-title":"Mol Cancer Therapeut"},{"issue":"5","key":"10.1016\/j.breast.2026.104741_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.24.00529","article-title":"Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-Positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP)","volume":"43","author":"Turner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104741_bib18","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104741_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15071987","article-title":"Emerging targeted therapies for HER2-Positive breast cancer","volume":"15","author":"Mercogliano","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104741_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.847835","article-title":"Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers","volume":"9","author":"Yu","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.breast.2026.104741_bib21","series-title":"European society for medical oncology (ESMO) congress","article-title":"SHR-A1811 versus pyrotinib plus capecitabine in HER2-positive advanced\/metastatic breast cancer (HORIZON-Breast01): results from a phase III study","author":"E","year":"2025"},{"issue":"22","key":"10.1016\/j.breast.2026.104741_bib22","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104741_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2026.104741_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01518520","article-title":"Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies","volume":"37","author":"Lewis","year":"1993","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.breast.2026.104741_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104741_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104741_bib27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.breast.2026.104741_bib28","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.breast.2026.104741_bib29","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/pro.2666","article-title":"Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate","volume":"24","author":"Marcoux","year":"2015","journal-title":"Protein Sci"},{"issue":"7","key":"10.1016\/j.breast.2026.104741_bib30","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.breast.2026.104741_bib31","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/neuonc\/noae123","article-title":"Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases","volume":"26","author":"Bartsch","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2026.104741_bib33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.breast.2026.104741_bib34","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"ARX788, a site-specific Anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"Mol Cancer Therapeut"},{"issue":"11","key":"10.1016\/j.breast.2026.104741_bib35","article-title":"Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma","volume":"3","author":"Zhang","year":"2022","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.breast.2026.104741_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040800","article-title":"Next-generation HER2-Targeted antibody-drug conjugates in breast cancer","volume":"16","author":"Zimmerman","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7_Supplement","key":"10.1016\/j.breast.2026.104741_bib37","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-2643","article-title":"Abstract 2643: BL-M07D1, a novel HER2-targeting ADC, demonstrates potent anti-tumor efficacy in preclinical pharmacodynamic models","volume":"83","author":"Wan","year":"2023","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.breast.2026.104741_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104741_bib39","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib40","first-page":"55","article-title":"Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities","volume":"4","author":"Endo","year":"2021","journal-title":"Antib Ther"},{"issue":"98","key":"10.1016\/j.breast.2026.104741_bib41","doi-asserted-by":"crossref","first-page":"37200","DOI":"10.18632\/oncotarget.26461","article-title":"Payload of T-DM1 binds to cell surface cytoskeleton-associated protein 5 to mediate cytotoxicity of hepatocytes","volume":"9","author":"Endo","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.breast.2026.104741_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ncb3295","article-title":"The LINK-A lncRNA activates normoxic HIF1alpha signalling in triple-negative breast cancer","volume":"18","author":"Lin","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"13","key":"10.1016\/j.breast.2026.104741_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133214","article-title":"CD33 expression and gentuzumab ozogamicin in acute myeloid leukemia: two sides of the same coin","volume":"13","author":"Molica","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-021-04254-w","article-title":"Cardiovascular toxicity of breast cancer treatment: an update","volume":"88","author":"Papageorgiou","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.breast.2026.104741_bib45","first-page":"407","article-title":"Trastuzumab-induced cardiomyopathy","volume":"37","author":"Barish","year":"2019","journal-title":"Cardiol Clin"},{"issue":"22","key":"10.1016\/j.breast.2026.104741_bib46","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMcibr1203156","article-title":"ERBB2 inhibition and heart failure","volume":"367","author":"Cote","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.breast.2026.104741_bib47","first-page":"913","article-title":"[Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer]","volume":"44","year":"2022","journal-title":"Zhonghua Zhongliu Zazhi"},{"issue":"2","key":"10.1016\/j.breast.2026.104741_bib48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jcjo.2021.02.028","article-title":"Reversible HER2 antibody-drug conjugate-induced ocular toxicity","volume":"57","author":"Sharma","year":"2022","journal-title":"Can J Ophthalmol"},{"issue":"8","key":"10.1016\/j.breast.2026.104741_bib49","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2026.104741_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.breast.2026.104741_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"10.1016\/j.breast.2026.104741_bib52","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.breast.2026.104741_bib53","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fimmu.2020.00740","article-title":"Fc\u03b3R binding and ADCC activity of human IgG allotypes","volume":"11","author":"de Taeye","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.breast.2026.104741_bib54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40259-018-0302-5","article-title":"Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody-drug conjugates","volume":"32","author":"Khera","year":"2018","journal-title":"BioDrugs"},{"issue":"10","key":"10.1016\/j.breast.2026.104741_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-Engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.breast.2026.104741_bib56","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1535-7163.MCT-22-0440","article-title":"Payload-binding fab fragments increase the therapeutic index of MMAE antibody-drug conjugates","volume":"22","author":"Bordeau","year":"2023","journal-title":"Mol Cancer Therapeut"},{"issue":"9","key":"10.1016\/j.breast.2026.104741_bib57","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12672-023-00616-3","article-title":"Chemotherapy-induced thrombocytopenia: literature review","volume":"14","author":"Gao","year":"2023","journal-title":"Discov Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1158\/1078-0432.CCR-14-2093","article-title":"Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)","volume":"21","author":"Uppal","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.breast.2026.104741_bib60","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1535-7163.MCT-16-0710","article-title":"Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol Cancer Therapeut"},{"issue":"11","key":"10.1016\/j.breast.2026.104741_bib61","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-24-2021","article-title":"Perivascular niche-resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment","volume":"85","author":"Wei","year":"2025","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2026.104741_bib62","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s12094-024-03383-x","article-title":"Safety profile of trastuzumab deruxtecan in advanced breast cancer: expert opinion on adverse event management","volume":"26","author":"Ciruelos","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104741_bib63","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12282-025-01670-1","article-title":"Management of nausea and vomiting induced by antibody-drug conjugates","volume":"32","author":"Farhat","year":"2025","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104741_bib64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10637-008-9152-1","article-title":"Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients","volume":"27","author":"Al-Dasooqi","year":"2009","journal-title":"Invest N Drugs"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH subcommittee on hemostasis and malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J Thromb Haemostasis"},{"issue":"7","key":"10.1016\/j.breast.2026.104741_bib66","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun"},{"issue":"2","key":"10.1016\/j.breast.2026.104741_bib67","first-page":"18","article-title":"Clinical practice guidelines on cancer-related anemia (2012-2013 Edition)","volume":"1","year":"2012","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.breast.2026.104741_bib68","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251324889","article-title":"Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer","volume":"17","author":"Kang","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"17","key":"10.1016\/j.breast.2026.104741_bib69","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"41","key":"10.1016\/j.breast.2026.104741_bib70","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.breast.2026.104741_bib71","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D'Arienzo","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.breast.2026.104741_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116013","article-title":"Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope","volume":"32","author":"Yamaguchi","year":"2021","journal-title":"Bioorg Med Chem"},{"issue":"suppl7","key":"10.1016\/j.breast.2026.104741_bib74","first-page":"S197","article-title":"460MO preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers","volume":"33","author":"Jhaveri","year":"2022","journal-title":"Ann Oncol"},{"issue":"48","key":"10.1016\/j.breast.2026.104741_bib75","doi-asserted-by":"crossref","first-page":"25106","DOI":"10.1074\/jbc.M116.753491","article-title":"Balancing selectivity and efficacy of bispecific epidermal growth factor receptor (EGFR) \u00d7 c-MET antibodies and antibody-drug conjugates","volume":"291","author":"Sellmann","year":"2016","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.breast.2026.104741_bib76","article-title":"Mechanisms underlying skin disorders induced by EGFR inhibitors","volume":"2","author":"Holcmann","year":"2015","journal-title":"Mol Cell Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104741_bib77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104741_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5040064","article-title":"Site-specific antibody conjugation for ADC and beyond","volume":"5","author":"Zhou","year":"2017","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.breast.2026.104741_bib79","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"19","key":"10.1016\/j.breast.2026.104741_bib80","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1158\/1078-0432.CCR-10-0987","article-title":"Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer","volume":"16","author":"Junutula","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104741_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114932","article-title":"Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation","volume":"392","author":"Simmons","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.breast.2026.104741_bib82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"16","key":"10.1016\/j.breast.2026.104741_bib83","article-title":"Machine learning-enabled drug-induced toxicity prediction","volume":"12","author":"Bai","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"12","key":"10.1016\/j.breast.2026.104741_bib84","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1021\/acs.analchem.4c00297","article-title":"Integrated electrochemical aptasensor array toward monitoring anticancer drugs in sweat","volume":"96","author":"Zhang","year":"2024","journal-title":"Anal Chem"},{"issue":"8","key":"10.1016\/j.breast.2026.104741_bib85","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104741_bib86","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-021-04250-0","article-title":"Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology","volume":"87","author":"Liu","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.breast.2026.104741_bib87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/psp4.12192","article-title":"Time-to-Event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens","volume":"6","author":"Lu","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"10.1016\/j.breast.2026.104741_bib88","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-Positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.breast.2026.104741_bib89","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:55:35Z","timestamp":1777600535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":89,"alternative-id":["S0960977626000512"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104741","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody\u2013drug conjugates in breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104741"}}